幽门螺杆菌(Helicobacter pylori,Hp)是全球最常见的感染源之一,目前普遍认为Hp与慢性活动性胃炎、消化性溃疡、胃黏膜相关性淋巴样组织淋巴瘤及胃癌相关。近年来,Hp的根除失败率逐渐上升,寻求新的根除策略迫在眉睫。针对Hp耐药性不断增加,一线方案根除率不断下降的现状,本研究借鉴国外先进治疗理念,提出新的采用根除Hp一线用药 Helicobacter pylori (Hp) is one of the most common sources of infection in the world. Hp is now generally considered to be associated with chronic active gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. In recent years, the rate of Hp eradication failure gradually increased, the search for a new eradication strategy is imminent. In view of the fact that Hp resistance is increasing and the eradication rate of first-line programs is declining, this study draws on the advanced foreign treatment concepts and proposes a new first-line eradication therapy using Hp